MUC1 Dendritic Cell Vaccine

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
MUC1 Dendritic Cell Vaccine
Accession Number
DB05477
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Description

Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system. Dendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells. Dendritic Cell Therapy involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce a greater than typical Dendritic Cell concentration. These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

Synonyms
Not Available
International/Other Brands
Cancer Vac / Cancer Vac Mannan-MUC1 / CVac
Categories
Not Available
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified) and ovarian cancer.

Pharmacodynamics

The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system. Dendritic Cell Therapy involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce a greater than typical Dendritic Cell concentration. These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

Mechanism of action

Use of increased concentration of dendritic cells to amplify immune responses to cancer.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother. 2004 Mar;53(3):240-8. Epub 2003 Dec 18. [PubMed:14685779]
  2. Conrad C, Nestle FO: Dendritic cell-based cancer therapy. Curr Opin Mol Ther. 2003 Aug;5(4):405-12. [PubMed:14513684]
  3. Vermorken JB, Van Tendeloo VF: Dendritic cell therapy of cancer: can it fulfill its promise? Expert Rev Anticancer Ther. 2003 Feb;3(1):1-3. [PubMed:12597344]
  4. Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG: Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer. 2002 May 20;86(10):1529-33. [PubMed:12085199]
  5. Grolleau A, Sloan A, Mule JJ: Dendritic cell-based vaccines for cancer therapy. Cancer Treat Res. 2005;123:181-205. [PubMed:16211871]
External Links
PubChem Substance
347910162

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionPlasmodium Infections1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentMetastatic Non-Small Cell Lung Cancer1
1TerminatedTreatmentLiver Cancer1
2CompletedTreatmentGlioblastomas1
2CompletedTreatmentOvarian Epithelial Cancer2
2Not Yet RecruitingPreventionPlasmodium Infections1
2TerminatedTreatmentOvarian Epithelial Cancer1
2WithdrawnTreatmentLocally Advanced Pancreatic Cancer / Pancreatic Carcinoma Stage I1
3Active Not RecruitingTreatmentAstrocytoma, Grade IV / Brain Cancer / GBM / Glioblastoma Multiforme (GBM) / Glioblastomas / Gliomas / Neoplasms, Brain1
3WithdrawnTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on November 18, 2007 11:25 / Updated on January 02, 2020 05:37